ANDA 202729, held by Accord Hlthcare. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 202729 (Fluoxetine Hydrochloride), held by Accord Hlthcare, was first approved by FDA on Aug 27, 2020, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 27, 2020 | Original application | Approved | None posted |
| Fluoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Fluoxetine HydrochlorideEQ 20MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Fluoxetine HydrochlorideEQ 40MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Feb 4, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 27, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters